Mimicking the action of Sex Hormone Binding Globulin (SHBG) effectively reduces ectopic fat, fibrosis and inflammation. Endolipid Tx is developing two novel peptides with validated efficacy - in vivo PoC: EDL6D for NASH and EDL3D for Cellulite/Slimming.

NASH is a growing and underserved disease. Endolipid Tx is developing EDL6D, an in vivo effective peptide that may offer a treatment opportunity for NASH with a novel and differentiated mechanism of action.

Cellulite and Slimming are poorly attended pathologies with scarce therapeutic innovation in the last 10 years. Endolipid Tx is developing EDL81, a peptide with a innovative mode of action and proven in vitro and in vivo efficacy in reducing ectopic fat in Cellulite and Slimming.

ENDOLIPID THERAPEUTICS

Org chart

Teams

Offices

ENDOLIPID THERAPEUTICS

Org chart

Teams

Offices

Related companies